Establishment of a disease-specific graded prognostic assessment for hepatocellular carcinoma patients with spinal metastasis

Chai Hong Rim, Chiwhan Choi, Jinhyun Choi, Jinsil Seong

Research output: Contribution to journalArticle

Abstract

Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0-2, 0 point; 3-4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 17.8%, and 7.3% for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalGut and liver
Volume11
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Hepatocellular Carcinoma
Neoplasm Metastasis
Survival
Radiotherapy
Survival Rate
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{83e35a28545c4d9aa32990581ca21644,
title = "Establishment of a disease-specific graded prognostic assessment for hepatocellular carcinoma patients with spinal metastasis",
abstract = "Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0-2, 0 point; 3-4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3{\%}, 17.8{\%}, and 7.3{\%} for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.",
author = "Rim, {Chai Hong} and Chiwhan Choi and Jinhyun Choi and Jinsil Seong",
year = "2017",
month = "7",
day = "1",
doi = "10.5009/gnl16486",
language = "English",
volume = "11",
pages = "535--542",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "4",

}

Establishment of a disease-specific graded prognostic assessment for hepatocellular carcinoma patients with spinal metastasis. / Rim, Chai Hong; Choi, Chiwhan; Choi, Jinhyun; Seong, Jinsil.

In: Gut and liver, Vol. 11, No. 4, 01.07.2017, p. 535-542.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Establishment of a disease-specific graded prognostic assessment for hepatocellular carcinoma patients with spinal metastasis

AU - Rim, Chai Hong

AU - Choi, Chiwhan

AU - Choi, Jinhyun

AU - Seong, Jinsil

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0-2, 0 point; 3-4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 17.8%, and 7.3% for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.

AB - Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0-2, 0 point; 3-4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 17.8%, and 7.3% for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85021822974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021822974&partnerID=8YFLogxK

U2 - 10.5009/gnl16486

DO - 10.5009/gnl16486

M3 - Article

VL - 11

SP - 535

EP - 542

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 4

ER -